The FDA decision on Patritumab deruxtecan, proposed for certain patients with previously treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer, is expected on June 26, 2024.Daiichi Sankyo (DSNKY.OB) and Merck have a global collaboration to jointly develop and commercialize Patritumab deruxtecan.The drug candidate is a specifically engineered potential first-in-class HER3 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology.If approved, Patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for the intended patient population.DSNKY.OB closed Wednesday’s trading at $34.24, down 1.81%.